drugset / Trial / NCT00255268
CMAB vs IMAB in Metastatic Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.
Timeline
- Start
- 2004-08
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | — | — |
| Subject | Goserelin | Other / unclassified | — | — |